HARBIN, China, Sept. 7 /PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that it will participate in the Rodman and Renshaw Annual Global Investment Conference on Tuesday, September 14th, 2010.
Conference: Rodman and Renshaw Annual Global Investment Conference
Date: Tuesday, September 14th 2010
Time: 4:30 - 4:55 PM ET
Location: Kennedy Salon (4th FL), New York Palace Hotel
New York, New York
Mr. Ren Hu, Vice President of Finance of Weikang, will present the Company's operations, business strategy, financial results, and outlook as well as answer investors' questions during the presentation and at one-on-one meetings.
Investors interested in attending the event should contact their Rodman and Renshaw sales representative. For more information about the conference, please visit http://www.rodmanandrenshaw.com/ .
About Weikang Bio-Technology Group Co., Inc.
Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang. For more information, please visit http://www.weikangbio.com .
Safe Harbor Statement
This press release contains certain statements that may include
"forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
For further information, please contact:
Company contact:
Ren Hu, VP of Finance
Weikang Bio-Technology Group Co., Inc.
US Cell: +1-201-887-0415
Email: arenhu@gmail.com
Investors Relation contacts:
John Marco, Partner, Elite IR
Tel: +1-310-819-2948
Email: John.marco@elite-ir.com
Leslie J. Richardson, Partner, Elite IR
Tel: +852-3183-0283
Email: Leslie.richardson elite-ir.com
